Therapeutic Technologies Research Initiative
Pharmaceuticals Discovery and Development workshop
Tuesday 14 June 2016
Theatre 3, Level 1 Alan Gilbert Building 104, The University of Melbourne

Program:

11:45 – 12:00 Registration.

12:00 – 12:30 Light lunch provided by Cortellis Competitive Intelligence.


14:15 – 14:40 Roundtable discussion on the importance of commercialisation.

14:40 – 14:45 Close by Prof Alastair Stewart, Dept of Pharmacology and Therapeutics.

Thomson Reuters Cortellis Competitive Intelligence provides drug pipeline analysis for over 61K drugs (including preclinical), 6 million patents, 6K deals, clinical trials, competitive and disease intelligence reports, sales forecasts, the latest news from conferences and more.

From one source you can create a full picture of the competitive and intellectual property landscape in your chosen area. All content is manually curated and indexed by our scientific editors enabling you to identify and track the competition by disease, mechanism of action or by chemical structure.

This session will give you an overview of Cortellis Competitive Intelligence and show you how Cortellis can answer questions such as:

- How are my competitors doing? What clinical milestones have they achieved?
- What biomarkers are in clinical investigation for breast cancer?
- What patenting activity has there been around my target/chemical structure in the last few months? Can I interrogate the intellectual property landscape around similar targets?
- What is the value of my drug asset/discovery?

Using disease briefings you can also easily access epidemiology and health/cost-burden information to support how your research provides a specific solution to an unmet medical need.
Dr Phillip Reece obtained a first class honours degree in organic chemistry at the University of Adelaide in 1972. Chemistry and mathematics had been his primary interests since high school but he wanted to apply them in biology. He chose to do a PhD in Medical Chemistry at the John Curtin School of Medical Research, Australian National University, Canberra which he completed in 1975. His thesis addressed the synthesis and biological activity of the marine toxins tetrodotoxin and saxitoxin.

Although accepted into a Post-Doctoral position in chemistry in the UK he was attracted to a permanent position in Clinical Pharmacology at the Queen Elizabeth Hospital, Adelaide in 1976. There he undertook research into drugs for hypertension and undertook undergraduate and postgraduate courses in pharmacokinetics. He was awarded a Churchill Fellowship in 1983 for research on the pharmacokinetics of anticancer drugs at the Mayo Clinic which he continued on his return to the Queen Elizabeth Hospital. The pharmaceutical industry beckoned and Phillip worked first at Astra, Sydney in 1987 and then Parke Davis, Sydney in 1989 on clinical trial management. He returned to the discipline of Clinical Pharmacology at Parke Davis, Ann Arbor Michigan in 1990, a position he held until late 1993.

Dr Reece contributed to the development of Parke Davis' highly successful drugs neurontin and quinapril. He returned to Australia as inaugural Director of Research and Development at Biota Holdings in 1993 and established a portfolio of projects, many of which are now in later development.

Since 2002, Dr Reece has held various positions in the biotechnology industry including CEO, Directorships and Chairmanship. He has also held long and short term consultancy roles in the biotechnology industry. He provides expert advice in pharmaceutical discovery and development, clinical pharmacology, and clinical trials to pharmaceutical and biotechnology companies. His specialities include: 1. Pharmaceutical research and development 2. Clinical pharmacology including pharmacokinetics 3. Phase I, II and III clinical trials.


Contact us: therapeutic-technologies@unimelb.edu.au
Website: [http://therapeutictechnologiesresearch.unimelb.edu.au](http://therapeutictechnologiesresearch.unimelb.edu.au)